Alkem laboratories has secured land allotment and board approval for a major manufacturing expansion in Madhya Pradesh. The pharmaceutical company received an official allotment letter on 18th March, while the Board of Directors has approved the substantial investment for the new formulations factory, marking a significant milestone in its growth strategy.

Land Acquisition Details

The company acquired 30 acres from DMIC Vikram Udyogpuri Limited for establishing its manufacturing presence in Ujjain. The strategic location offers advantages for distribution across central and western India.

Board Approval and Investment Plan

The Board of Directors has approved a substantial investment of up to ₹533 crores for the Ujjain facility development. The company plans to implement the project through a structured approach to optimize resource utilization and operational efficiency.

Strategic Significance

The Ujjain facility represents Alkem Laboratories' commitment to expanding its manufacturing footprint across India. The greenfield facility will enable the company to enhance production capacity for formulations, supporting its growth in the pharmaceutical sector. The phased investment approach allows for systematic development while maintaining financial discipline.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of the SEBI LODR Regulations. The company has committed to making this information available on its website in accordance with regulatory requirements, ensuring transparency with stakeholders and maintaining compliance with listing obligations.

Alkem Laboratories has successfully obtained EU GMP certification for its manufacturing facility at Baddi, India, marking a significant regulatory achievement for the pharmaceutical company. The Certificate of GMP Compliance was issued by the Department of Pharmacy (Human Medicines) – Germany following a comprehensive inspection of the facility.

Inspection Details and Certificate Validity

The German Health Authority conducted the inspection from 4th November 2025 to 10th November 2025, spanning seven days of thorough evaluation. The resulting certificate demonstrates the facility's compliance with European Good Manufacturing Practice standards.

Regulatory Compliance and Disclosure

The company announced this development in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This follows an earlier intimation dated 10th November 2025 regarding the EU GMP inspection by the German Health Authority at the Baddi facility.

Strategic Significance

The EU GMP certificate enables Alkem Laboratories to manufacture pharmaceutical products at its Baddi facility in accordance with European regulatory standards. This certification is crucial for companies seeking to supply pharmaceutical products to European markets, as it demonstrates adherence to stringent quality and manufacturing standards.

The three-year validity period provides the company with a substantial timeframe to leverage this certification for its European market operations. The company has made the disclosure available on its website in accordance with regulatory requirements under Regulation 30(8) of the SEBI LODR Regulations.